Literature DB >> 9625315

Transforming growth factor-beta1 in autoimmune hepatitis: correlation of liver tissue expression and serum levels with disease activity.

E M Bayer1, W Herr, S Kanzler, C Waldmann, K H Meyer Zum Büschenfelde, H P Dienes, A W Lohse.   

Abstract

BACKGROUND/AIMS: Transforming growth factor-beta1 (TGF-beta1) is considered the most important mediator of hepatic fibrogenesis. At the same time, TGF-beta1 is an immunosuppressive cytokine. Development of fibrosis, often rapid, is a characteristic of autoimmune hepatitis, as is spontaneous systemic immunosuppression. The aim of our study was therefore to define the role of TGF-beta1 in autoimmune hepatitis. METHODS/
RESULTS: Using the MV 1Lu bioassay, we found markedly elevated serum levels of TGF-beta1 (median 109 ng/ml) in active autoimmune hepatitis, which normalised when patients reached biochemical remission following immunosuppressive therapy (median 34 ng/ml; p=0.0001 compared to active disease). With a newly established ELISPOT-assay for TGF-beta1-producing cells, we could exclude an increase in TGF-beta1-producing peripheral blood cells as a source of the elevated TGF-beta1. However, by in situ hybridisation and immunohistochemistry, we found strong TGF-beta1 expression in the inflamed liver. In addition to non-parenchymal and infiltrating cells, many hepatocytes showed strong staining for TGF-beta1. TGF-beta1 expression in the liver normalised in remission, yet was still somewhat increased in patients with biochemical remission but remaining histological disease activity.
CONCLUSIONS: These results suggest that TGF-beta1 is an important mediator in active autoimmune hepatitis. They support the theory that immunosuppressive therapy needs to be guided by histology, as prevention of the development of cirrhosis presumably requires near complete suppression of TGF-beta1 in the liver; this is only found when there is no longer any histological evidence of inflammation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9625315     DOI: 10.1016/s0168-8278(98)80230-4

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  10 in total

1.  Aberrant TGF-β1 signaling contributes to the development of primary biliary cirrhosis in murine model.

Authors:  Bin Liu; Xuan Zhang; Feng-Chun Zhang; Jin-Bao Zong; Wen Zhang; Yan Zhao
Journal:  World J Gastroenterol       Date:  2013-09-21       Impact factor: 5.742

2.  Inhibition of TGF-beta signaling by an ALK5 inhibitor protects rats from dimethylnitrosamine-induced liver fibrosis.

Authors:  Anne-Charlotte de Gouville; Valerie Boullay; Gael Krysa; Julia Pilot; Jean-Marie Brusq; Florence Loriolle; Jean-Michel Gauthier; Stephen A Papworth; Alain Laroze; Françoise Gellibert; Stephane Huet
Journal:  Br J Pharmacol       Date:  2005-05       Impact factor: 8.739

3.  TGF-beta(1) genotype and accelerated decline in lung function of patients with cystic fibrosis.

Authors:  P D Arkwright; S Laurie; M Super; V Pravica; M J Schwarz; A K Webb; I V Hutchinson
Journal:  Thorax       Date:  2000-06       Impact factor: 9.139

4.  The clinical value of serum connective tissue growth factor in the assessment of liver fibrosis.

Authors:  Dai Zhang; Nian-Yue Wang; Cheng-Bao Yang; Guo-Xiang Fang; Wei Liu; Jian Wen; Chan Luo
Journal:  Dig Dis Sci       Date:  2009-03-18       Impact factor: 3.199

5.  Signaling through the interleukin-4 and interleukin-13 receptor complexes regulates cholangiocyte TMEM16A expression and biliary secretion.

Authors:  Amal K Dutta; Kristy Boggs; Al-Karim Khimji; Yonas Getachew; Youxue Wang; Charles Kresge; Don C Rockey; Andrew P Feranchak
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2020-02-24       Impact factor: 4.052

6.  TGF-β1 T869C polymorphism may affect susceptibility to idiopathic pulmonary fibrosis and disease severity.

Authors:  Ji Young Son; Song Yee Kim; Sang Ho Cho; Hyo Sub Shim; Ji-Ye Jung; Eun Young Kim; Ju Eun Lim; Byung Hoon Park; Young Ae Kang; Young Sam Kim; Se Kyu Kim; Joon Chang; Moo Suk Park
Journal:  Lung       Date:  2013-01-24       Impact factor: 2.584

Review 7.  Immune Inhibitory Properties and Therapeutic Prospects of Transforming Growth Factor-Beta and Interleukin 10 in Autoimmune Hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2021-04-09       Impact factor: 3.199

8.  Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis.

Authors:  Elena Turola; Salvatore Petta; Ester Vanni; Fabiola Milosa; Luca Valenti; Rosina Critelli; Luca Miele; Livia Maccio; Vincenza Calvaruso; Anna L Fracanzani; Marcello Bianchini; Nazarena Raos; Elisabetta Bugianesi; Serena Mercorella; Marisa Di Giovanni; Antonio Craxì; Silvia Fargion; Antonio Grieco; Calogero Cammà; Franco Cotelli; Erica Villa
Journal:  Dis Model Mech       Date:  2015-07-16       Impact factor: 5.758

9.  Stellate Cell Activation and Imbalanced Expression of TGF-β1/TGF-β3 in Acute Autoimmune Liver Lesions Induced by ConA in Mice.

Authors:  Liyun Wang; Lei Tu; Jinping Zhang; Keshu Xu; Wei Qian
Journal:  Biomed Res Int       Date:  2017-01-29       Impact factor: 3.411

Review 10.  Organ Fibrosis and Autoimmunity: The Role of Inflammation in TGFβ-Dependent EMT.

Authors:  Margherita Sisto; Domenico Ribatti; Sabrina Lisi
Journal:  Biomolecules       Date:  2021-02-18
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.